- Signed to supply of molecular diagnostic instruments and COVID-19 kits in $4 million to Qatar
- Qatar Petroleum will supply instruments and kits to medical institutions in Qatar.
[Daejeon, Republic of Korea – April 7, 2020] Bioneer (CEO Han-oh Park) specializing in molecular diagnostics announced that it has signed an agreement with Qatar Petroleum, a state-owned company, to supply $4 million molecular diagnostic instruments and coronavirus detection kits in Qatar.
Under the agreement, Bioneer will supply Qatar Petroleum with COVID-19 molecular diagnostic kits, nucleic acid extraction reagents and 18 molecular diagnostic instruments such as ExiPrep™ 96 Lite and Exicycler™. Supplied instruments and kits for COVID-19 molecular diagnosis will be applied in medical institutions including the Medical Services Department of Qatar Petroleum.
Bioneer provides a total solution for molecular diagnosis with its gene extraction instrument, real-time PCR instrument, extraction reagents and assays for amplifying and analyzing genes required for COVID-19 detection and diagnostics. All Bioneer’s instruments, reagents and kits are developed by the proprietary technologies in-house.
Bioneer supplies COVID-19 related diagnostic instruments and kits to various countries around the world, including a recent $1.9 million agreement to supply its molecular diagnostic system ExiStation™ and COVID-19 detection kits in Romania.
Bioneer said that “Bioneer’s molecular diagnostic system ExiStation™ is based on Real-Time PCR and RNA extraction equipment. It is equipped with an automated system and can be operated after short-term training.”
The company added that in addition to COVID-19, Bioneer’s molecular diagnostic instrument is capable of testing various infectious diseases, such as HIV, Hepatitis B, Hepatitis C, Sexually Transmitted Infections and Tuberculosis using a molecular diagnostic kit developed by the company.
About the ExiStation™ system
The ExiStation™ was developed and launched by BIONEER, and it is the automatic molecular diagnostic system composed of nucleic acid extractor, ExiPrep™ and real-time PCR, Exicycler™.
Bioneer is the first and only company in Asia to receive CE-IVD, List A certification for HIV-1, HBV, and HCV assays with ExiStation™, which was based on the results of comparative clinical trials with Roche’s COBAS 8800 system.
The ExiStation™ is an automated molecular diagnostic system, which can reduce the error of the inspector and derive quick and accurate test results. The system can be expanded and configured according to the size of the laboratory, the number of specimens, and the type of tests.
About the COVID-19 test kit
Bioneer received CE-mark certification for ‘AccuPower® COVID-19 Real-Time RT-PCR Kit’ and ‘AccuPower® SARS-CoV-2 Real-Time RT-PCR Kit’.
It leverages the company’s original patented technology Dual-HotStart™. It can detect RNA target from clinical samples with high sensitivity and specificity through eliminating non-specific synthesis and amplification.
About BIONEER Corporation
Established in 1992, BIONEER is the first Korean biotechnology company with aim of the complete localization of genetic technology and is publicly traded at KOSDAQ since 2005.
BIONEER’s multiplex molecular diagnostics kit for the ZIKA, dengue and chikungunya viruses was listed in Emergency Use Assessment and Listing (EUAL) from WHO in 2016.
In 2018, BIONEER received its first CE-IVD, List A mark for HIV diagnosis kit and afterwards, it was registered on the purchase list of international non-profit financing organization, Global Fund.
In 2019, BIONEER received its second CE-IVD, List A mark for HCV diagnosis kit.
In 2020, BIONEER received its third CE-IVD, List A mark for HBV diagnosis kit and its HCV diagnosis kit was registered on the purchase list of Global Fund.